

Please note that the following document was created by the former Australian Council for Safety and Quality in Health Care. The former Council ceased its activities on 31 December 2005 and the Australian Commission on Safety and Quality in Health Care assumed responsibility for many of the former Council's documents and initiatives. Therefore contact details for the former Council listed within the attached document are no longer valid.

The Australian Commission on Safety and Quality in Health Care can be contacted through its website at <http://www.safetyandquality.gov.au/> or by email [mail@safetyandquality.gov.au](mailto:mail@safetyandquality.gov.au)

Note that the following document is copyright, details of which are provided on the next page.

The Australian Commission on Safety and Quality in Health Care was established in January 2006. It does not print, nor make available printed copies of, former Council publications. It does, however, encourage not for profit reproduction of former Council documents available on its website.

Apart from not for profit reproduction, and any other use as permitted under the Copyright Act 1968, no part of former Council documents may be reproduced by any process without prior written permission from the Commonwealth available from the Attorney General's Department. Requests and inquiries concerning reproduction and rights should be addressed to Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>



ROYAL ADELAIDE HOSPITAL - PHARMACY DEPARTMENT  
CYTOTOXIC DRUG PRODUCTION MASTER INSTRUCTION RECORD

DRUG: <b>VINCRIStINE SULFATE</b>	Computer Code: VINC IA (intra-arterial infusion) VINC IF (IV infusion) VINC IV (IV bolus)
Other names: VCR, leurocristine sulfate, Oncovin	
Class: vinca alkaloid, antimitotic	

**PRODUCT INFORMATION:**  
\* stability data ex Trissel 11<sup>th</sup>. Edition

To minimise the possibility of vincristine ever being given intrathecally and causing a fatality, **ALL bolus injections will now be supplied in a 50 mL mini-bag** of sodium chloride 0.9% injection solution rather than in a syringe.

**SPILL AND EXTRAVASATION INFORMATION:**  
For spills:

Eyes: Hold eyelids open under a gently running cold tap for at least 15 minutes. May cause irritation, pain, swelling, sensitivity to light or watering of eyes.  
Seek medical attention.

Skin: Remove from exposure immediately and remove all contaminated clothing. Wash affected area with copious quantities of water.  
Seek medical attention

For extravasation: follow standard procedure for treatment of extravasation steps 1 to 4.  
Topical hyaluronidase (Lasonil) may be applied.  
AVOID cold compress, use warm compress.

**SAMPLE LABEL:**

KEEP OUT OF REACH OF CHILDREN  
Pharmacy Department  
Royal Adelaide Hospital

CYTOTOXIC INJECTION SOLUTION  
VINCRIStINE  
2 MG IN 52 ML  
J SAMPLE U.R.12345 DC  
ROUTE OF ADMINISTRATION:IV  
RATE: over 5 minutes  
B:0840436 Exp. 30/08/2004  
PROTECT FROM LIGHT

R.A.H. PHARMACY  
**FOR INTRAVENOUS USE ONLY**  
FATAL IF GIVEN BY OTHER ROUTES

KEEP OUT OF REACH OF CHILDREN  
Pharmacy Department  
Royal Adelaide Hospital

CYTOTOXIC INJECTION SOLUTION  
VINCRIStINE  
2 MG IN 1002 ML  
J SAMPLE U.R.12345 DC  
ROUTE OF ADMINISTRATION:IF  
RATE: over 24 hours  
B:0840437 Exp. 30/08/2004  
PROTECT FROM LIGHT

**WARNING**  
**DO NOT EXTRAVASATE**

**REFRIGERATE**  
DO NOT FREEZE

R.A.H. PHARMACY  
**FOR INTRAVENOUS USE ONLY**  
DO NOT REMOVE COVERING UNTIL  
MOMENT OF INJECTION  
FATAL IF GIVEN BY OTHER ROUTES

**MASTER PREPARED BY:** V.A. Shanley  
**Date:** 23 Aug 04

**MASTER CHECKED BY:** N.A. Shanley  
**Date:** 3 Sep 2004

Reviewed Date:	Reviewed Date:	Reviewed Date:	Reviewed Date:	Reviewed Date:	Reviewed Date:
Reviewed Date:	Reviewed Date:	Reviewed Date:	Reviewed Date:	Reviewed Date:	Reviewed Date: